Illumina, Inc. (FRA:ILU)
Market Cap | 13.10B |
Revenue (ttm) | 3.66B |
Net Income (ttm) | 1.07B |
Shares Out | n/a |
EPS (ttm) | 6.75 |
PE Ratio | 12.22 |
Forward PE | 21.15 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 84 |
Average Volume | 304 |
Open | 81.34 |
Previous Close | 81.51 |
Day's Range | 81.34 - 85.05 |
52-Week Range | 62.29 - 146.32 |
Beta | n/a |
RSI | 54.86 |
Earnings Date | Oct 31, 2025 |
About Illumina
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole... [Read more]
Financial Performance
In 2024, Illumina's revenue was $4.37 billion, a decrease of -2.93% compared to the previous year's $4.50 billion. Losses were -$1.22 billion, 5.34% more than in 2023.
Financial numbers in USD Financial StatementsNews
Final Trades: Illumina, Columbia Banking, Alibaba and JPMorgan Chase
The Investment Committee give you their top stocks to watch for the second half.
Final Trades: Illumina, Columbia Banking, Alibaba and JPMorgan Chase
The Investment Committee give you their top stocks to watch for the second half.
KMDA or ILMN: Which Is the Better Value Stock Right Now?
KMDA vs. ILMN: Which Stock Is the Better Value Option?
Illumina (ILMN) Unveils Groundbreaking 5-Base Solution for Advanced Multiomic Analysis
Illumina (ILMN) Unveils Groundbreaking 5-Base Solution for Advanced Multiomic Analysis

Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights
At ASHG, an early access customer from the London Health Sciences Center Research Institute will demonstrate the power of the 5-base genome for accelerating resolution of rare disease cases Proprietar...

Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot
Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx Constellation outperformed orthogonal methods in identifying select difficult-to-map vari...

Illumina to Announce Third Quarter 2025 Financial Results on Thursday, October 30, 2025
SAN DIEGO , Oct. 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2025 following the close of market on Thursday, October 30, 202...
Illumina (ILMN) Shares Cross Below 200 DMA
In trading on Tuesday, shares of Illumina Inc (Symbol: ILMN) crossed below their 200 day moving average of $98.17, changing hands as low as $96.50 per share. Illumina Inc shares are currently trading ...
Illumina (ILMN) Analyst Rating Update: Evercore ISI Lowers Price Target | ILMN Stock News
Illumina (ILMN) Analyst Rating Update: Evercore ISI Lowers Price Target | ILMN Stock News
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ILMN Stock Set to Benefit From the Launch of New BioInsight Division
Illumina launches BioInsight to harness multiomic data, accelerate drug discovery, and boost disease diagnosis.
ILMN: Barclays Raises Price Target, Maintains Underweight Rating | ILMN Stock News
ILMN: Barclays Raises Price Target, Maintains Underweight Rating | ILMN Stock News
Illumina to Join Pharma Partners for CDx Development on KRAS Biomarker
ILMN partners with pharma leaders to advance KRAS-focused companion diagnostics through its TruSight Oncology platform.
Illumina (ILMN) Launches BioInsight to Enhance Biologic Data Interpretation
Illumina (ILMN) Launches BioInsight to Enhance Biologic Data Interpretation

Illumina launches new business to accelerate technology and data-driven discovery
New business focuses on developing data assets, software, and AI to fuel life science breakthroughs Expands pharma access to large omics datasets to advance target discovery and drug development SAN D...

ILMN Stock vs. IQV Stock
Amid increased competition from China's MGI Tech, Illumina's stock (NASDAQ: ILMN) has dropped by 11% in a week. MGI Tech's DNA sequencers are reportedly gaining market share, and despite a recent decl...
TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now?
As precision oncology advances, Tempus and Illumina lead the way with innovation. Which stock shows stronger growth momentum now?
Illumina (ILMN) Expands Precision Oncology Efforts with New Partnerships
Illumina (ILMN) Expands Precision Oncology Efforts with New Partnerships

Illumina advances personalized cancer care with new pharma development partnerships
Illumina and pharma partners will develop companion diagnostics for historically important KRAS biomarker SAN DIEGO , Sept. 23, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) will partner with mult...

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine
Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D...
Bullish Two Hundred Day Moving Average Cross - ILMN
In trading on Tuesday, shares of Illumina Inc (Symbol: ILMN) crossed above their 200 day moving average of $101.59, changing hands as high as $102.00 per share. Illumina Inc shares are currently tradi...

CDC vaccine panel to meet this week: Here's what's at stake
Scott Gottlieb, former FDA commissioner and current board member of Pfizer and Illumina, joins CNBC's 'Squawk on the Street' to discuss expectations for a CDC panel's review of vaccines this week, wha...
ILMN January 2028 Options Begin Trading
Investors in Illumina Inc (Symbol: ILMN) saw new options begin trading today, for the January 2028 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is...

Chinese biotech firm MGI’s DNA sequencers gaining in the market, BGI CEO says
DNA sequencers from Chinese firm MGI Tech can rival those from global market leader Illumina in spite of US sanctions, according to Yin Ye, CEO of BGI Group, former parent of the Shenzhen-based biotec...

Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development
Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease Following early access program, custome...